CION Ameerpet
An allogeneic transplant uses healthy stem cells from a matched donor, so a new immune system can fight remaining lymphoma — the graft-versus-lymphoma effect. This guide explains the donor stem cell transplant clearly, and how CION coordinates it with accredited transplant partners.
An allogeneic transplant — often shortened to an allo transplant, and also called a donor stem cell transplant — replaces your blood-forming (haematopoietic) stem cells with healthy stem cells collected from a matched donor. The donor might be a brother or sister, an unrelated matched donor found through a registry, or in some cases a half-matched (haploidentical) family member.
What makes an allogeneic transplant different from other treatments is not just the new blood cells — it is the new immune system that comes with them. Once the donor cells engraft, the donor immune cells can recognise any remaining lymphoma cells as foreign and destroy them. Doctors call this the graft-versus-lymphoma effect, and it is the reason a donor transplant can offer durable, sometimes curative, control for selected people with relapsed or refractory lymphoma when other options have not worked.
This is a complex, coordinated procedure. To understand where it sits among all the options, start with our stem cell transplant overview, and for the full care pathway see Lymphoma Treatment in Hyderabad or the main Lymphoma hub.
The graft-versus-lymphoma effect — where donor immune cells attack residual lymphoma — is the defining advantage of an allogeneic transplant over an autologous one. It is closely linked to graft-versus-host disease, so transplant teams balance the two carefully. This is why donor transplants are reserved for carefully selected patients and delivered at dedicated, accredited transplant facilities. (Source: NCCN and ESMO clinical practice guidelines for Hodgkin and non-Hodgkin lymphoma.)
Both are stem cell transplants, but the source of the cells — and therefore the mechanism — is completely different. In lymphoma, an autologous transplant is used far more often; an allogeneic transplant is reserved for selected relapsed or high-risk cases.
| Feature | Autologous transplant | Allogeneic (donor) transplant |
|---|---|---|
| Stem cell source | Your own cells, collected earlier | A matched donor (sibling, unrelated or half-matched) |
| Main mechanism | Rescue after high-dose chemotherapy | Graft-versus-lymphoma immune effect |
| Graft-versus-host disease | Does not occur | A key risk that is monitored and managed |
| Typical role in lymphoma | Common; first transplant option for many | Selected relapsed / refractory or high-risk cases |
| Delivered | Coordinated at an accredited partner facility | Coordinated at an accredited partner facility |
This table is a general guide; the right choice is individualised and made within a multidisciplinary team following NCCN and ESMO guidance. Both transplant types are coordinated through accredited partner facilities, not delivered in-house.
A donor transplant is only as good as the planning around it. Getting the lymphoma into the best possible control beforehand, choosing the right moment, and managing the recovery all shape the outcome.
Transplant outcomes improve when the lymphoma is well controlled going in. CION's team delivers the chemotherapy, immunotherapy and targeted therapy needed to achieve that control directly, before any transplant referral.
Whether a donor transplant, an autologous transplant or CAR T-cell therapy is the better path is decided at a multidisciplinary tumour board, weighing subtype, prior treatment and fitness against NCCN and ESMO frameworks.
The transplant itself is performed at a dedicated, accredited transplant facility. CION arranges the referral, shares your work-up, and stays involved throughout — the procedure is coordinated, never delivered in-house.
After transplant, monitoring for infection, engraftment and graft-versus-host disease, plus long-term survivorship care, are wrapped around you. See how we handle treatment side effects.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
If your lymphoma has come back or not responded, and you want to know whether an allogeneic transplant is an option for you, CION's team can review your case and coordinate the right pathway.
An allo transplant for lymphoma is a carefully sequenced process. Each stage is planned in advance and delivered by an experienced transplant team at an accredited facility, with CION coordinating your journey.
The team searches for the best-matched donor — first among siblings, then unrelated donor registries, and if needed a half-matched (haploidentical) family member. Matching is based on tissue-typing markers rather than blood group, and a good match lowers the risk of complications.
Before the donor cells are given, you receive conditioning — chemotherapy, sometimes with radiation — to reduce the lymphoma and make room for the new cells. Depending on age and fitness, this may be full-intensity or a gentler reduced-intensity regimen, which relies more on the graft-versus-lymphoma effect.
The donor stem cells are infused much like a blood transfusion. Over the following weeks they travel to the bone marrow and begin producing new blood and immune cells — a stage called engraftment. During this period, careful protection against infection is essential.
After engraftment, the focus shifts to preventing and managing complications — especially graft-versus-host disease — and rebuilding strength. Immune-suppressing medicines (described here by drug class, not brand) are used to keep the new immune system in balance. Follow-up continues for months to years.
An allogeneic transplant is powerful precisely because it introduces a new immune system — but that same feature is the source of its main risks. Being clear-eyed about them is part of an honest decision.
GVHD occurs when donor immune cells attack your own tissues — most often the skin, gut and liver. It can be acute (in the early months) or chronic (later), and ranges from mild to serious. Because GVHD is closely tied to the beneficial graft-versus-lymphoma effect, the two are balanced rather than eliminated. Teams reduce and treat GVHD with immune-suppressing medicines and vigilant monitoring.
While the new immune system is rebuilding, the risk of infection is high, so preventive measures, screening and prompt treatment are central. This is a key reason a donor transplant is carried out at a facility with dedicated transplant expertise and infrastructure.
For the right person, the chance of long-term, sometimes curative, control can justify these risks. For others, an autologous transplant, CAR T-cell therapy, or continued immunotherapy and antibody or clinical-trial options may be more appropriate. This is exactly the kind of finely balanced decision a tumour board is built for.
It is natural to want a number, but honest answers about an allogeneic transplant are always individualised. Outcomes depend on the lymphoma subtype, how well the disease is controlled before transplant, the quality of the donor match, and your age and overall fitness.
For broad context, published series report that overall lymphoma survival varies widely by type — for example, Hodgkin lymphoma survival is often around 80–90% and diffuse large B-cell lymphoma around 60–70% in published data. These are general, whole-population figures, not transplant-specific promises, and figures vary by individual. What a donor transplant offers selected people with relapsed or refractory disease is the chance of durable, sometimes curative, control through the graft-versus-lymphoma effect when standard treatments have not been enough.
Your transplant team, working within NCCN and ESMO frameworks, will give you a realistic, personalised estimate — and will be honest about both the potential benefit and the risks. Book a consultation to discuss your specific situation.
A reduced-intensity conditioning (RIC) allogeneic transplant uses gentler pre-transplant treatment and leans more on the donor immune system's graft-versus-lymphoma effect than on high-dose chemotherapy. This has made donor transplants an option for selected older or less-fit patients who could not tolerate a full-intensity regimen. (Source: NCCN and ESMO clinical practice guidelines for lymphoma.)
Because a donor transplant is a major decision with real trade-offs, a second opinion is especially valuable when:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. For an idea of what transplant care involves financially, see our stem cell transplant cost guide. You can also meet our lymphoma doctors or learn about our lymphoma hospital in Hyderabad. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if your disease has relapsed or you are choosing between transplant, CAR T-cell therapy and other options.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.An allogeneic transplant — often called an allo transplant or a donor stem cell transplant — replaces your blood-forming stem cells with healthy stem cells from a matched donor. The donor may be a sibling, an unrelated matched donor from a registry, or in some cases a half-matched family member. After high-dose conditioning treatment, the donor cells are infused and rebuild your bone marrow. Crucially, the new donor immune system can recognise and attack any remaining lymphoma cells — an effect called graft-versus-lymphoma. This makes an allogeneic transplant a potentially curative option for selected people with relapsed or refractory lymphoma. It is a coordinated procedure carried out at an accredited transplant partner facility, planned with your CION team.
In an autologous transplant, your own stem cells are collected, stored and given back to you — so it acts mainly as a rescue after high-dose chemotherapy. An allogeneic (allo) transplant uses cells from a matched donor instead. The key advantage is the graft-versus-lymphoma effect, where the donor immune system helps destroy residual disease. The trade-off is a higher risk of complications, chiefly graft-versus-host disease and infection, because a new immune system is establishing itself. Autologous transplant is used far more often in lymphoma; allogeneic transplant is generally reserved for selected relapsed or high-risk cases. Our stem cell transplant overview compares the two approaches in more detail.
An allogeneic transplant is considered for selected people whose lymphoma has come back or did not respond to earlier treatment, particularly when disease persists after an autologous transplant or when the lymphoma subtype is aggressive or high-risk. Suitability depends on the lymphoma type and current control, your age and overall fitness, organ function, and the availability of a well-matched donor. Because a donor immune system is involved, candidates are assessed carefully by a transplant team. According to NCCN and ESMO guidance, the decision is individualised and made within a multidisciplinary team. At CION, your case is reviewed by our tumour board, and a transplant referral is coordinated with an accredited partner facility when appropriate. Ask for an eligibility review.
Graft-versus-host disease is a complication unique to allogeneic (donor) transplants. It happens when the donor immune cells — the graft — recognise your body's tissues as foreign and attack them. It can affect the skin, gut and liver, and ranges from mild and manageable to serious. GVHD is closely related to the beneficial graft-versus-lymphoma effect, so the two are balanced carefully. Transplant teams reduce and treat GVHD using immune-suppressing medicines (described by drug class, not by brand) and close monitoring. Preventing and managing GVHD is a central part of the specialist follow-up after an allo transplant, and is one reason the procedure is delivered at an accredited transplant partner facility with dedicated expertise.
CION provides coordinated care around the transplant journey. Our medical oncology and haematology team manages the lymphoma before transplant — including chemotherapy, immunotherapy and targeted therapy to get the disease under the best possible control, which improves transplant outcomes. We arrange the pre-transplant work-up, molecular and imaging assessment, and the multidisciplinary review, then coordinate a referral to an accredited transplant partner facility where the allogeneic transplant is actually performed. Afterwards, we support survivorship, monitoring and management of late effects. The transplant itself is not delivered in-house; CION's role is to plan, refer and wrap supportive care around it. See our lymphoma treatment page for the full pathway.
Outcomes depend heavily on the lymphoma subtype, how well the disease is controlled going into transplant, the donor match, your age and fitness. For selected people with relapsed or refractory disease, an allogeneic transplant can achieve long-term remission — and in some cases a cure — through the graft-versus-lymphoma effect, when other options have failed. Published series report that broad lymphoma survival varies widely (for example Hodgkin lymphoma around 80–90% and diffuse large B-cell lymphoma around 60–70% overall, per published data), but these are general figures for lymphoma as a whole, not transplant-specific promises. Figures vary by individual. Your transplant team, following NCCN and ESMO frameworks, will give you a realistic, personalised estimate based on your situation.
Both an allogeneic transplant and CAR T-cell therapy are options for certain relapsed or refractory lymphomas, and both are coordinated through accredited partner facilities rather than delivered in-house. The choice depends on the lymphoma subtype, previous treatments, disease control, donor availability and fitness. In general, CAR T-cell therapy has become a leading option for several aggressive B-cell lymphomas, while an allogeneic transplant may be considered when a durable donor-immune (graft-versus-lymphoma) effect is the goal, or after other therapies including transplant have been used. These are complex, individualised decisions best made within a multidisciplinary team. CION reviews your case at tumour board and helps you weigh the options — book a consultation to discuss which pathway fits.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.